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ABSTRACT
Several human diseases in Europe are caused by viruses transmitted by tick bite. These viruses belong to
the genus Flavivirus, and include tick-borne encephalitis virus, Omsk haemorrhagic fever virus, louping
ill virus, Powassan virus, Nairovirus (Crimean-Congo haemorrhagic fever virus) and Coltivirus (Eyach
virus). All of these viruses cause more or less severe neurological diseases, and some are also
responsible for haemorrhagic fever. The epidemiology, clinical picture and methods for diagnosis are
detailed in this review. Most of these viral pathogens are classified as Biosafety Level 3 or 4 agents, and
therefore some of them have been classified in Categories A–C of potential bioterrorism agents by the
Centers for Disease Control and Prevention. Their ability to cause severe disease in man means that
these viruses, as well as any clinical samples suspected of containing them, must be handled with
specific and stringent precautions.
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TICK-BORNE ENCEPHALITIS VIRUS
DISEASES
After the recognition of tick-borne encephalitis
(TBE) as a distinct disease entity by Schneider in
1931 [1], the causative tick-borne encephalitis
virus (TBEV) was discovered by Zilber in 1937
in far-eastern Russia [2]. TBEV and antigenically
closely related viruses have since been isolated in
regions stretching from northern Asia to central
and western Europe. The data show that TBEV is
present in at least 25 European and seven Asian
countries.
Virus properties and taxonomy
TBE virions have an average diameter of 50 nm
and possess two membrane-anchored surface
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proteins, i.e., the envelope glycoprotein E and
the small membrane protein M. The genome
consists of a positive single-stranded RNA mole-
cule of c. 11 000 nucleotides that encodes a large
polypeptide (c. 3400 amino-acids), which is
co- and post-translationally cleaved and proc-
essed by host-cell and virus enzymes to yield
three structural and seven non-structural proteins
[3]. The open reading frame of all flaviviruses is
flanked by 5¢ and 3¢ untranslated RNA regions
that form secondary stem–loop structures; these
probably serve as cis-acting elements for genome
amplification, translation and packaging [4–6].
According to the classification scheme of the
International Committee for Taxonomy of Vir-
uses, TBEV (family Flaviviridae, genus Flavivirus)
is a single virus species with three subtypes,
designated European, Siberian and Far-Eastern,
respectively [7].
Ecology
TBE is an infectious zoonotic disease that occurs
in so-called natural foci, risk or endemic areas,
all of which refer to the occurrence of a specific
agent during a constant period of time within the
borders of a particular location. Virus activity
within such risk areas and the geographical
distribution of agents within the foci may vary
[8,9]. TBEV is maintained in nature in a cycle
involving ticks and wild vertebrate hosts.
The vectors are haematophagous ticks that
remain infected throughout their life cycle. The
ticks transmit the disease agent to vertebrate hosts
when feeding, having picked up the agent from
reservoirs which may or may not be in a viraemic
state. Although many different species of tick are
biologically competent to transmit TBEV in the
laboratory, in nature only Ixodes ricinus in Europe,
and Ixodes persulcatus and Haemaphysalis concinna
in Russia, appear to play a significant role in virus
maintenance, largely because of specific ecologi-
cal limiting factors [10]. Virus transmission from
infected to uninfected ticks occurs through the
migratory skin cells of vertebrates [11]. This
process forms an important focus of virus repli-
cation in the absence of systemic viraemia [12]
and occurs when naı¨ve ticks feed on vertebrate
hosts close to infected ticks, a process known as
co-feeding. In the laboratory, this has been shown
to be an efficient means of transmission of TBEV
and other tick-borne viruses among ticks [12–16],
and the typical pattern of aggregated distributions
of larval and nymphal ticks within rodent popu-
lations ensures a sufficient level of transmission in
nature [17,18]. Obviously, the feeding of naı¨ve
ticks on viraemic vertebrates may also play a role
in the natural cycle of TBEV. The relative import-
ance of each mechanism has been modelled [17],
but has not yet been determined clearly in the
field. In order for transmission to occur, the virus
must be capable of multiplication within the
vector. The vector then carries the pathogen to a
range of hosts that play different roles within
natural foci. A host may be a carrier of the
pathogen without automatically contributing to
the cycle of pathogen transmission. Therefore, it is
helpful to apply specific terms to divide the hosts
into reservoir, indicator and accidental hosts.
The reservoirs are wild-living vertebrates cap-
able of transmitting infection. Within natural foci,
these reservoirs are present in high numbers, and
have a high reproduction rate and a rapid
generation turnover. In the case of TBEV, they
must be receptive to the virus and enable the
virus to multiply and be delivered to feeding
ticks. If viraemia develops with a high virus titre,
it should not cause host death before the ticks
have completed their blood meal [16]. These are
not characteristics seen in small rodent species
infected with TBEV, where, if viraemia develops,
it is short-lived (several days) [19] and can be fatal
before ticks complete their blood meal [20]; in
hosts shown to infect a high proportion of feeding
ticks, virus titres reach only low levels. Experi-
ments on non-viraemic transmission have shown
that viraemia is not a condition necessary for
successful transmission to ticks. For ticks, in
contrast to insect vectors, a reservoir host plays
an active (albeit accidental) role in the vector–
reservoir relationship by sweeping questing ticks
from vegetation; indeed, with relatively immobile
ticks, it is the host’s movement that is instrumen-
tal in picking up ticks [21]. In the case of TBEV,
small rodent species are short-lived reservoirs of
the virus, whereas ticks maintain the virus within
natural foci for many months or even years.
Indicator hosts cannot transmit the virus to
other vectors, either because they can endure only
a brief period of viraemia with low virus titres, or
because they lack the necessary cell-based mech-
anisms to support non-viraemic transmission [12].
Experimental work during the 1990s showed that
this statement is not true—Apodemus mice are
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recognised as the most significant transmission
hosts in the field, yet develop only low virus
titres. Thus, there must be other reasons why
indicator species are not competent to transmit,
e.g., they lack the necessary cell-based mecha-
nisms. Man, and large animals such as goats,
cows, sheep, deer, dogs and swine, can become
infected accidentally, but there is experimental
evidence that ungulates are not competent to
transmit the virus back to feeding ticks [22].
Indirectly, these species support virus circulation
by enabling the ticks themselves to survive and
reproduce [23]. Seroprevalence in these large
vertebrates may represent an indirect means of
measuring the intensity of TBEV transmission
within a geographical region [24]. Therefore, they
constitute valuable sentinel species for antibody
detection in epidemiological studies.
Accidental hosts are species that can be infected
by the pathogen and can develop viraemia, but
generally neither participate in virus circulation
nor form a significant nutrition source for ticks.
Epidemiology
Since ticks remain infected throughout their life
cycle, the epidemiology of TBE is clearly related
closely to the ecology and biology of ticks, with
regard to not only their distribution but also the
seasonality of tick feeding activity [25]. The
seasonal dynamics of ticks determine the poten-
tial for co-feeding transmission among ticks, and
also the risk to humans from infected questing
nymphal ticks. I. ricinus is the dominant hard tick
species across Europe and is the most important
vector for European TBEV. I. persulcatus inhabits
forest regions of the Urals, Siberia and far-eastern
Russia, and is the main transmission vector for
TBEV of the Siberian and Far-Eastern subtypes.
I. persulcatus exists also in parts of the Baltic States
(Estonia, Latvia). In Russia, TBEV has also been
isolated sporadically from 18 other tick species,
such as Dermacentor spp. and Hyalomma spp. [26];
however, these species probably do not contribute
significantly to the epidemiology of human dis-
ease. The prevalence of ticks infected with TBEV
in endemic areas in Europe usually varies from
0.5% to 5% [27,28], although prevalence rates of
40% have been recorded in certain regions of
Russia [24]. It is important to note that methods
for measuring virus prevalence in ticks have not
yet been standardised.
Human cases of TBE usually occur between
April and November, when infected ticks are
questing for hosts. TBEV infections in humans can
show considerable year-to-year variation; for
instance, certain regions of Russia, that typically
reported 700–1200 cases annually, recorded up to
10 000 cases in the post-Perestroika era, probably
because of a large increase in outdoor activities
[29] and a simultaneous drastic decrease in the
use of pesticides. The highest incidence has been
registered in Latvia, the Urals and western Sibe-
rian regions of Russia, where attack rates range
from 115 to 199 reported cases ⁄ 100 000 inhabit-
ants ⁄ year [30]. However, attack rates in the range
of 50–60 ⁄ 100 000 inhabitants are more typical
(V. I. Zlobin, unpublished results). It is estimated
that c. 3000 cases occur in western European
countries annually, giving a typical incidence of
< 4 cases ⁄ 100 000 inhabitants (http://www4.tbe-
info.com/epidemiology/). Nevertheless, the inci-
dence of TBE has increased during the past
20 years, and the virus is now found in previ-
ously unaffected areas. A link between observed
changes in climate and changes in vector distri-
bution and TBE incidence has been suggested
[31,32], but the increase in TBE in Sweden from
1984 onwards seemed to occur independently of
the increase in recorded temperatures [33], which
began in 1989.
The European subtype comprises almost all
known isolates from Europe and has been found
in I. ricinus as well as in I. persulcatus (Latvia) [28].
Strains of the Siberian subtype are typically
isolated in the Urals, Siberia and far-eastern
Russia, while the Far-Eastern subtype is isolated
in far-eastern Russia, China and Japan [34].
However, Siberian and Far-Eastern subtypes of
TBEV have been isolated recently in Europe
[28,35,36].
Routes of TBEV infection
The most likely way for a human to become
infected with TBEV is to be bitten by an infected
tick during outdoor activities in forest areas
where dense vegetation can sustain large num-
bers of ticks. However, 70–95% of human infec-
tions in endemic regions are either sub-clinical or
totally asymptomatic [24,37]. The major factor
contributing to the incidence of the disease in
man is an abundance of ticks containing a
sufficient dose of infectious TBEV [29]. Although
the highest incidence of human infections
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coincides with seasonal peaks in the feeding
activity of I. ricinus (May–June and September–
October) and I. persulcatus (May–June), a substan-
tial proportion of patients do not report a history
of tick bite [38]. TBEV infections have been
diagnosed serologically or by virus isolation in
Austria, Belarus, Bosnia, Croatia, China, the
Czech Republic, Denmark, Estonia, Finland,
France, Germany, Greece, Hungary, Italy, Japan,
Kazakhstan, Latvia, Lithuania, Norway, Poland,
Romania, Russia, Serbia, the Slovak Republic,
Slovenia, Sweden, Switzerland and the Ukraine
[2,24]. Epidemiological and surveillance data
regarding TBE from 27 European countries and
the Far East, including China and Japan, have
been reviewed elsewhere [39].
A second natural route for the acquisition of
TBEV infection is associated with the consumption
of raw goats’ milk [24,40]. TBEV has been isolated
repeatedly from the milk of infected goats for up to
25 days after collection; infectivity is maintained
in various milk products such as yoghurt, cheese
and butter. Persistent infectivity in gastric juice is
observed after ingestion of such products for up to
2 h [41], while pasteurisation prevents milk-borne
TBEV infection [2]. However, confirmation based
on recent experimental data is currently lacking.
Data regarding the alimentary route and other
transmission routes for TBEV not involving tick
bites have been reviewed elsewhere [39].
Laboratory-acquired cases of infection have
been reported in the context of accidental needle-
stick injuries or aerosol generation and contam-
ination through the olfactory pathway [42,43].
Clinical and standard laboratory features
Acute phase
After an incubation period of 7–14 days (with
extremes of 4–28 days), the first phase consists of
the sudden onset of an uncharacteristic influenza-
like illness with fever, headache, joint and back
pain, and accompanying symptoms such as nau-
sea and vomiting; this phase usually lasts for
4 days (range 1–8 days) [44,45]. Biologically, this
phase is commonly characterised by thrombope-
nia, leukopenia and hyperalbuminorachia. A bi-
phasic course is common and occurs in 74–87% of
cases [46]. After an 8-day symptom-free interval
(range 1–33 days), a second phase occurs in which
meningoencephalitis presents in 20–30% of
infected patients [47]. In the second phase, neu-
rological signs occur, and this is usually the time
when patients with fever and severe headache
consult a physician. In the remaining individuals
(13–26%), the disease resolves without a second
phase. It is important to note for the anamnestic
history that a substantial proportion of TBE
patients recognised the tick bite. Encephalitic
symptoms during the second phase include men-
ingeal signs, ataxia and cognitive disorders such
as impaired concentration and memory, dyspha-
sia, altered consciousness, confusion, irritability,
tremor, and paralysis of cranial nerve and respir-
atory muscles. The fatality rate in Europe is < 1%.
Long-term morbidity
Sequelae characterised by neurological and neu-
ropsychiatric symptoms are often reported. Time
to recovery is extended over several months,
generally with a good outcome [48]. Common
symptoms are various cognitive and focal neuro-
logical signs. Hearing defects have been reported
with high frequency in certain studies [49,50].
Post-encephalitis syndrome includes diverse
manifestations such as spinal nerve paralysis,
neuropsychiatric complaints, dysphasia, ataxia
and paresis; occurrence of such a syndrome has
been correlated with increased age, impaired
consciousness during the acute phase, with or
without ataxia and paralysis, a history of assisted
ventilation, abnormal findings on magnetic res-
onance imaging, pleiocytosis of > 300 cells ⁄lL in
cerebrospinal fluid (CSF), and impairment of the
blood–CSF barrier [45,51,52].
Our understanding of the pathogenic mecha-
nisms of TBE is incomplete. The difficulties
associated with detecting virus RNA in CSF
during the encephalitic phase strongly suggest
that virus replication may be inhibited or reduced
when neutralising antibodies appear in serum
and CSF, although the virus may be located in
neurones [53]. Low levels of neutralising serum
antibodies correlate with a severe course of the
disease. The theory of antibody-dependent
enhancement, which originated from clinical
studies of dengue fever [54,55], has been consid-
ered, but there are no laboratory data indicative of
a similar phenomenon in human TBE.
A remarkable characteristic of TBEV infections
is the existence of chronic forms [56,57]. This
seems to be an Asian–Russian phenomenon, and
such chronic forms have not so far been observed
in western Europe. Further investigations are
Charrel et al. Tick-borne diseases 1043
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 1040–1055
needed into the clinical, virological and patho-
physiological features, but these forms are char-
acterised by neurological symptoms that appear
progressively without being preceded by a
recognised acute phase. Symptoms are progres-
sive neuritis, lateral sclerosis, dispersed sclerosis,
Parkinson-like disease or progressive muscular
atrophy [24]. In such cases, TBEV has been
identified as the aetiological agent only by virus
isolation [58–60]. Molecular diagnostic methods
that will allow the possibility of excluding cross-
contamination during virus isolation procedures
are now available.
Association of pathogenesis with TBEV subtype
and geographical location
Despite their antigenic similarities, it is possible to
distinguish three variants of TBEV, i.e. Central
European, Siberian and Far-Eastern, on the basis
of serological tests. Nucleotide and amino-acid
sequence analysis has validated the divergent
nature of these three variants despite their close
biological similarities [3,61,62]. Human infections
in far-eastern regions are usually severe with
frequent encephalitic signs, a fatality rate of
5–35% [2] and an absence of chronic forms [24].
In contrast, TBEV infections in Siberian–Ural
regions present as a less severe disease (fatality
rate of 1–3%), but chronic forms seem to be more
frequent. Experimental evidence for the associ-
ation of Siberian strains with chronic forms has
been derived from monkey and Syrian golden
hamster model systems [58–60,63–65]. Infections
caused by European strains are typically biphasic
and are characterised by a viraemic phase with
fever, malaise, headache, myalgia, leukocytope-
nia, thrombocytopenia and elevated liver en-
zymes; after a 1-week latency period, 25% of
patients develop clinical signs of neurological
involvement [44,47,66]. Residual sequelae are
observed in c. 25–50% of patients, but < 2% of
cases are fatal [45].
A cluster of eight fatal cases was reported
recently in the Novosibirsk region of Russia
(Siberia); these cases were caused by strains with
the Far-Eastern genetic pattern. Surprisingly,
these patients suffered a pronounced haemor-
rhagic syndrome with massive gastrointestinal
bleeding and multiple haemorrhages in mucosa
and internal organs [67]. Numerous experimental
data demonstrate pathogenic differences between
European and Far-Eastern strains on the one
hand, and between Far-Eastern and Siberian
strains on the other. More specifically, Far-Eastern
strains have a clear tropism for neurones, thereby
accounting for the degenerative manifestations
associated frequently with infection. However,
the molecular mechanisms responsible for the
different pathogenic features remain obscure [24].
Increasing numbers of clinical and subclinical
cases of TBE have also been documented in dogs
[68].
Collection and preservation of samples
TBEV is classified as a Biosafety Level 3 (BSL-3)
agent. Therefore, all procedures involving biolo-
gical samples must be performed according to
stringent safety rules.
Serum or heparinised plasma should be collec-
ted during the acute febrile stages of the disease.
The samples must be frozen on dry ice or in liquid
nitrogen because storage at temperatures above
) 40C results in progressive loss of infectivity.
Direct diagnosis was previously achieved by
virus isolation (see below), but may now be
performed with an RT-PCR assay. If inoculation
into cell culture (or suckling mice) or RT-PCR has
to be delayed for > 24 h, the plasma or buffy coat
layer should be frozen in liquid nitrogen (or at
) 70C if intended for isolation procedures). Stor-
age at ) 20C is suitable for molecular methods.
For serological diagnosis, blood samples
should be collected early in the course of the
disease, with a second sample obtained after a
further 1–2 weeks. If a four-fold rise in antibody
titre has not occurred, a third serum sample,
collected after 4–6 weeks, may be useful. Samples
collected for serological diagnosis can be kept at
) 20C. TBEV-specific antibodies are usually
detected by enzyme-linked immunosorbent assay
(ELISA). When results are being interpreted, it
should be remembered that TBEV is a flavivirus
and therefore shares several antigenic deter-
minants with mosquito-borne viruses such as
Dengue virus, Japanese encephalitis virus or West
Nile virus. Specific identification can usually be
achieved with neutralisation tests.
Field studies often result in the collection of
ticks that are suitable for analysis for the presence
of TBEV. Ticks should be tested for the TBEV
genome with RT-PCR techniques, since large
numbers of samples can be tested in a short time
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period with high sensitivity. Classically, ticks are
crushed in 500–1000 lL of phosphate-buffered
saline containing fetal bovine serum 20% v ⁄ v; an
aliquot is used for total RNA extraction and
subsequent RT-PCR, while the remainder is
stored at ) 80C for virus isolation in those cases
where the TBEV genome is detected. A detailed
protocol is available upon request from the
corresponding author.
Tools available for diagnosis
TBEV isolation can be achieved through virus
propagation after inoculation of serum and ⁄ or
CSF into mammalian cell cultures (Vero, BHK-21,
PK, RH, 293 or A549 cells) or the brains of
suckling mice. Alternatively, the TBEV genome
can be detected with RT-PCR from either blood or
CSF during the first phase of the disease. How-
ever, these techniques are of minor diagnostic
importance in practice, since most patients con-
sult a physician only during the second phase of
the disease, when the virus has already been
cleared from blood and CSF. Moreover, in con-
trast to many other virus infections, including
those with other flaviviruses, RT-PCR is not very
useful for the laboratory diagnosis of TBE, since
even the most sensitive molecular methods fre-
quently fail to detect virus RNA during the first
phase [53,69]. Newer real-time RT-PCR tech-
niques merit further evaluation of their usefulness
in TBE diagnostic procedures [2,70]. RT-PCR for
the detection of TBEV RNA has been used
successfully in epidemiological surveys of virus
prevalence in ticks and for the investigation of
viraemia in vertebrate hosts [71–74]. However, it
is important to underline that virus isolation and
molecular techniques do not play a significant
role in the routine diagnosis of TBE, which is
based mainly on the presence of specific antibod-
ies, usually detected at the beginning of the
second phase.
Before the 1980s, paired sera were tested with
complement fixation [75] or haemagglutination
inhibition tests [76]. For rapid diagnosis, specific
IgM antibodies were detected by 2-mercaptoeth-
anol reduction in haemagglutination inhibition
tests. ELISA is now the method of choice for
serological diagnosis on paired sera. ELISAs may
be performed on serum or CSF. Rapid diagnosis is
performed by detecting IgM with capture ELISA,
which avoids false-positive results caused by the
interference of rheumatoid factor or heterophilic
antibodies [69]. Detection of IgM antibodies to
TBEV in serum or CSF by ELISA has been shown
to be the most reliable serological test [77]. How-
ever, the suitability of IgM for assessment during
early diagnosis is questionable, since IgM anti-
bodies can persist for up to 10 months in vaccinees
or individuals who acquired the infection natur-
ally. Therefore, confirmation by detection of spe-
cific IgG with ELISA or a seroneutralisation test is
recommended.
It should be noted that the results of antibody
tests may be negative in the early phase of
infection, and the tests should therefore be repea-
ted 1–2 weeks later, and that commercial ELISAs
show great variation with regard to specificity
and sensitivity [78]. For a more satisfactory
analysis of the immune response against TBEV,
knowledge of previous infections with other
flaviviruses (Dengue, etc.) and ⁄ or vaccinations
(yellow fever, Japanese encephalitis, TBE, etc.) is
helpful because of the cross-reactivity of the
antibodies [79]. Verification of the diagnosis with
specific IgG detection is necessary. However, for
cases with other flavivirus contacts (e.g. vaccin-
ation against yellow fever or Japanese encephal-
itis; Dengue virus infections), a neutralisation
assay is necessary because of the interference of
flavivirus cross-reactive antibodies in ELISA and
haemagglutination inhibition tests [80]. Moreover,
both IgG and IgM antibodies perform well in
neutralisation tests.
Therapy and prevention
There is no drug with demonstrated efficacy
against flaviviruses. Other than the avoidance of
exposure to the bite of an infected tick, vaccin-
ation is the most effective means of disease
prevention. Two vaccines are available currently
in western Europe (FSME-IMMUN, Baxter Vac-
cine AG, Vienna, Austria; and Encepur, Chiron-
Behring, Marburg, Germany), prepared with
Austrian and German strains, respectively, that
are closely related genetically. FSME-IMMUN is
the vaccine used most widely in Europe; this
vaccine has been improved progressively over
time, and consists of whole purified virus of the
European TBEV subtype, propagated in chick
embryo cells and inactivated with formaldehyde
[81,82]. The basic immunisation protocol consists
of two vaccinations given approximately 1 month
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apart, followed by a third vaccination after 1 year.
Booster immunisations are recommended every
3–5 years, giving a protection rate of 96–98% [83].
A so-called ‘accelerated schedule’ has been pro-
posed, consisting of three doses at days 0, 7 and
21 [84], with a further dose after 1 year to
complete the basic immunisation protocol. Fol-
lowing mass vaccination in Austria, active sur-
veillance revealed a dramatic decline in the
incidence of TBEV infection [83,85]. Currently,
there are also two vaccines available for children
that contain half of the adult dose, FSME-IMMUN
Junior (Baxter) and Encepur Kinder (Chiron-
Behring) [81,82]. Normally, there is a very low
rate of non-serious and serious adverse reactions
other than post-vaccination fever [81]. Both vac-
cines have been used widely to immunise infants
and children in the high-risk areas of Austria and
Germany [82,84,86]. Although the full recommen-
ded vaccination schedule requires 1 year, an
accelerated schedule (at days 0, 7 and 21) achieves
a similar efficacy, despite a slight increase in side
effects [84]. Although the vaccine is manufactured
exclusively from the European subtype, immune
protection could be provided against all three
subtypes [87]. Accordingly, it is reasonable to
recommend immunisation for unexposed indi-
viduals travelling to endemic areas, and for
laboratory workers performing TBEV propaga-
tion.
In Russia, tissue culture inactivated vaccines
were developed in 1960 [88], and the results of
extended field trials of these vaccines have been
reported [89]. Currently, two vaccines are avail-
able, prepared from the Far-Eastern subtype (205
and Sofjin strains) of TBEV. ENCEVIR (Virion,
Tomsk, Russia) has been available since 2001,
while the other has been produced at the Insti-
tute of Polyomyelitis and Viral Encephalitis
(Moscow, Russia) since 1984; both are certified
for children. These vaccines consist of formal-
dehyde-inactivated, purified and concentrated
TBEV, and have been used for mass vaccination
(up to 7 million doses) in Russia. For both
vaccines, the primary course of vaccination con-
sists of three doses.
In Russia, prevention of TBE also includes the
use of specific immunoglobulins, which are active
when administered to tick-bitten persons within 3
days post-bite. This therapy is reported to be
effective in 98% of cases in a curative context and
100% in a prophylactic context (i.e., administered
to individuals before visiting natural foci of TBEV
(V. A. Lashkevich, personal data)). In Europe,
TBE immunoglobulin first lost its licence for
children aged up to 14 years because of a suspec-
ted association between post-exposure applica-
tion of immunoglobulin and very severe forms of
the disease. It was then withdrawn completely
from the market and is no longer available. It is
likely that such preventive and ⁄ or curative meth-
ods will have little future because of safety
regulations regarding the use of human-derived
products for treating humans.
OMSK HAEMORRHAGIC FEVER
Agents and vectors
Omsk haemorrhagic fever virus (OHFV) was first
recognised following several outbreaks during
1943–1945 in the rural region of the Omsk district
in Siberia. The virus was first isolated from a
patient’s blood in 1947, and later from ticks
belonging to the species Dermacentor reticulatus
(Dermacentor pictus), muskrats and other verte-
brates and arthropods. According to the Interna-
tional Committee for Taxonomy of Viruses,
OHFV is a unique species of the genus Flavivirus
within the family Flaviviridae [7]. This delinea-
tion is based on a clear-cut antigenic difference
between OHFV and TBEV, demonstrated with
monoclonal antibodies [90]. These findings were
corroborated by genetic distances calculated from
complete coding sequences between OHFV and
TBEV of 10.2–11.6% at the amino-acid level [91]
(R. N. Charrel, personal data). However, there is
no morphological difference between OHFV and
TBEV; both have virions with an average diam-
eter of 50 nm that possess two envelope glyco-
proteins (E and M). The genomic characteristics
are also similar to those of TBEV (see previous
sections).
The natural foci of OHFV are in the Omsk and
Novosibirsk regions, and also in Kurgan and
Tyumen (western Siberia), which comprise fores-
ted areas and open wetlands. The typical land-
scape associated with OHFV is forest–steppe. The
highest incidence of OHFV disease was observed
in the years following World War II; sub-
sequently, a substantial decline in case numbers
has been recorded, probably linked to the immu-
nisation of the local population against TBEV and
OHFV, and a decrease in the vector population.
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The classic route of transmission is a tick bite
during outdoor activity in forest areas and nearby
wetlands situated in the endemic region. Typic-
ally, cases occur from April to December. Spring
cases correlate with the activity of the vector
D. reticulatus. A second peak may be observed
during August–September, correlating with the
feeding activity of a second vector, Dermacentor
marginatus [92]. Collaborative studies led by the
Institute of Poliomyelitis and Viral Encephalitis
and the Omsk Institute for Natural Focal Infec-
tions [93] established that D. reticulatus was the
natural reservoir, in which OHFV was trans-
stadially and trans-ovarially maintained through-
out the tick life cycle.
However, in recent years, most human cases
have been related to direct contact with musk-
rats (Ondatra zibethica), and usually occur during
the hunting season from September to October
[94]. Of 165 cases of OHFV recorded in 1988–
1997, only ten involved the classic route of
transmission (tick bite) [95]. Muskrats can
become infected through both the alimentary
and respiratory routes (the virus has been
isolated from urine and faeces), and OHFV
transmission in muskrat populations results in
a prevalence rate as high as 14%. Therefore,
muskrats possess all the characteristics of a
potent amplifier host for OHFV. In contrast to
other arthropod-borne viruses, OHFV is highly
pathogenic for its main host (muskrat). It is
interesting that muskrats were first introduced
into Siberia from Canada in 1928. This suggests
that OHFV has been in contact with its new host
for only 75 years, during which time it may
have shown some degree of co-evolution. For
unknown reasons, the OHFV endemic area is
much smaller than the areas in which Derma-
centor ticks and muskrats are distributed.
Clinical and standard laboratory features
The incubation period is usually 3–7 days, with
extremes of 1–10 days. In contrast to TBEV,
OHFV infection does not involve the central
nervous system (hence the absence of major
neurological signs), and the principal disorders
are vascular and circulatory, with capillary dam-
age being responsible for the haemorrhagic man-
ifestations. The onset is sudden, with fever lasting
for 5–12 days. There may be remission of the
fever, after which 30–50% of patients experience a
second febrile phase, commonly more severe than
the first. Common features include fever, head-
ache, myalgia, cough and gastrointestinal symp-
toms. Haemorrhage (epistaxis, bleeding gums,
metrorrhagia, haematemesis) is not severe and
does not impair the prognosis, but in some cases,
signs of vascular fragility, such as petechial rash
and bruises at the puncture sites, can be observed.
Blood analysis often reveals leukopenia and
thrombocytopenia. During the second phase,
patients can develop meningeal signs, but neuro-
logical involvement has not been reported. Recov-
ery is usually slow, but sequelae are unusual.
Mortality rates range from 0.5% to 3% [96].
More extensive information can be obtained from
reviews published previously [97,98].
Collection and preservation of samples
The procedures for collection and preservation of
samples are essentially as described above for
TBEV. The only difference is that OHFV is
classified as a BSL-4 agent in most European
countries except France, where it is considered as
a BSL-3 agent.
Tools available for diagnosis
The tools available for diagnosis are as described
above for TBEV.
Therapy and prevention
Therapy and prevention are as described above
for TBEV. There is evidence of cross-protection
between OHFV and TBEV, so TBEV vaccines are
likely to be reasonably effective in the prevention





Crimean-Congo haemorrhagic fever virus
(CCHFV) is a tick-borne virus of the genus
Nairovirus within the family Bunyaviridae.
Morphologically, CCHFV resembles other bunya-
viruses, with a spherical, enveloped virion 90–
120 nm in diameter. The CCHFV genome consists
of three molecules of negative-sense single-stran-
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ded RNA, each encapsulated separately. The
virion particle contains three major structural
proteins, i.e., two envelope glycoproteins G1 and
G2, and a nucleocapsid protein. The virus glyco-
proteins play a role in: (1) the recognition of
receptor sites on susceptible cells; (2) the haem-
agglutination process; and (3) the induction of an
immune response by a vertebrate host. The
nucleocapsid protein is involved in the synthesis
of complement-fixing antibody.
CCHFV is distributed widely in Africa, the
Middle East and central and southwestern Asia. It
has also been found in parts of Europe, specific-
ally Rostov, Stavropol, Astrakhan and some other
southern provinces of Russia [99–102], Bulgaria
[103], Greece [104], the Kosovo province of the
former Yugoslavia [105,106] and Albania [107].
There is also very limited serological evidence for
the presence of the virus in parts of Hungary,
France and Portugal. In general, the prevalence of
antibodies to CCHFV in livestock and human
populations coincides with the distribution of
Hyalomma ticks.
CCHFV causes disease in man, but generally
asymptomatic infections in other mammals,
except newborn laboratory mice, rats and Syrian
hamsters (A. M. Butenko, personal data). The
virus has been isolated from at least 30 species of
tick, including 28 Ixodidae and two Argasidae
spp. However, it is unlikely that argasids are
capable of serving as vectors, since CCHFV does
not replicate in these ticks following intra-coel-
omic inoculation. Many ixodid tick species, e.g.,
Hyalomma marginatum, Rhipicephalus rossicus and
D. marginatus, display numerous properties that
make them principal (or efficient) vectors: (1)
they are capable of acquiring CCHFV infection
through feeding on viraemic hosts; (2) infection
can persist trans-stadially from one stage of the
tick life cycle to the next (larva, nymph, adult),
and thereafter be transmitted successfully to a
second host; (3) trans-ovarial transmission to
their progeny has been observed; (4) co-feeding
has also been demonstrated to be an important
mechanism for tick-to-tick infection, as for tick-
borne flaviviruses; and (5) infected male ticks are
able to transmit CCHFV to the female via the
venereal route, and subsequent trans-ovarial
dam-to-progeny transmission has been observed.
While many ixodids are capable of transmitting
CCHFV, members of the genus Hyalomma are the
most efficient vectors. Epidemiological data,
based on reports of human CCHFV infections
and the results of serological studies, confirm
that Hyalomma ticks are the principal transmit-
ters of the infection in nature [99].
Seroepidemiological studies conducted in dif-
ferent endemic regions of Europe, Africa and Asia
have shown that large herbivores (the principal
hosts of adult Hyalomma spp.) exhibit the highest
antibody prevalence, and that birds generally lack
antibodies (birds appear to be refractory to
CCHFV infection, but it is not clear whether this
simply reflects lack of exposure), with the major
exception being ostriches, which are known to be
parasitised by Hyalomma ticks. This is particularly
important given the increasing importation of
ostriches to breeding farms in western Europe.
Evidence of infection of other birds (hornbills,
starlings and guinea fowl) has been obtained in
Senegal [108].
Many animal species, when viraemic for
CCHFV, have been shown to infect feeding ticks.
From an epidemiological point of view, small
vertebrates such as hares may be the most
important host for the perpetuation of the virus
in nature, since, unlike large vertebrates, they are
infested by immature ticks that are more likely to
transmit CCHFV trans-stadially, and thus act as
amplifying hosts. CCHFV infection in man can
occur: (1) through tick bite or crushing infected
ticks in ungloved hands; (2) via the nosocomial
pathway in homes and hospitals [109–111];
(3) from contact with blood or other infected
tissues of livestock; (4) by drinking raw milk from
infected animals [112]; or (5) via the transcutane-
ous or respiratory pathway in laboratory workers.
Most cases are reported in individuals, e.g.,
shepherds, dairy workers, veterinarians, farmers
and, occasionally, slaughterhouse staff, who have
occupational contacts with livestock.
Clinical and standard laboratory features
After an incubation period, estimated at 2–7 days,
onset is sudden, with fever, chills, headache,
dizziness, neck pain, nuchal rigidity, photopho-
bia, retro-orbital pain, myalgia and arthralgia.
Non-focal digestive manifestations, such as nau-
sea, vomiting, diarrhoea and abdominal pain, are
encountered frequently. Haemorrhagic manifes-
tations occur after several days of illness, and
include petechial rash, ecchymoses, haemate-
mesis and melena, and are often associated with
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thrombocytopenia and leukopenia. Hepatitis is
associated frequently with jaundice, hepatomeg-
aly and elevated levels of transaminase enzymes.
Generally, petechiae precede the haemorrhagic
signs, which consist of bleeding from venepunc-
ture sites, and large bruises and ecchymoses in
the axilla and inguinal regions. The mortality rate
is c. 30% (varying from 10% to 60%, depending
on region and transmission route). Death occurs
mainly after 6–10 days of illness as a result
of profuse haemorrhages, haemorrhagic pneu-
moniae, and disturbance of vital cardiovascular
functions. Cardiovascular disturbances include
tachycardia, bradycardia and low blood pressure.
Individuals who recover do not usually experi-
ence sequelae other than a persistent asthenia.
Although there is a lack of documentation regard-
ing non-hospitalised cases, it is believed that there
are few subclinical cases; further investigations
are required to confirm this hypothesis.
Several biological parameters can be affected
during the course of the disease, of which the
most frequently reported are: (1) leukopenia; (2)
thrombocytopenia; (3) elevated levels of aspartate
transaminase, alanine transaminase, c-glutamyl
transferase, lactic dehydrogenase, alkaline phos-
phatase, creatine kinase, bilirubin, creatinine and
urea; and (4) declining levels of serum proteins.
Disorders in the coagulation pathways can lead to
elevation of thrombin time, fibrin degradation
products and a decrease in the amount of fibrin-
ogen. The appearance of all these disorders early
in the course of the disease suggests that dissem-
inated intravascular coagulation is an early and
central event in the pathogenesis of CCHFV
infection.
Collection and preservation of samples
As CCHFV is a BSL-4 pathogen, all procedures
involving patient management and handling of
infectious materials must be performed with
extreme caution in accordance with appropriate
national guidelines and legislation (see [113] for
those applicable in the USA).
Direct diagnosis
Serum or heparinised plasma should be collected
during the acute febrile stages of the disease, and
the samples must be frozen on dry ice or in liquid
nitrogen. Storage at a temperature above ) 40C
will result in progressive loss of infectivity.
Classically achieved by virus isolation, direct
diagnosis may now be performed with RT-PCR.
When inoculation (for isolation in cell culture or
suckling mice) or RT-PCR has to be delayed for
> 24 h, plasma or buffy coat layer should be
frozen in liquid nitrogen or at ) 70C for isolation
procedures, or at ) 20C for molecular methods.
Indirect diagnosis
Samples collected for serological diagnosis can be
kept for long periods at ) 20C or below without
degradation of antibodies. A blood sample should
be collected early in the course of the disease,
with a second sample after 1 or 2 weeks. If a four-
fold rise in antibody titre has not occurred, a third
serum sample taken after 4–6 weeks can be
useful. Blood obtained in the early convalescence
period may be infectious, despite the presence of
antibodies, and therefore should be handled with
appropriate precautions.
Tools available for diagnosis
Serology
IgG and IgM antibodies can be detected with
ELISA and indirect immunofluorescence tests
from about day 7 of illness. Specific IgM declines
to undetectable levels by 4 months post-infection,
but IgG remains detectable for at least 5 years.
Serological diagnosis is made: (1) by demonstra-
tion of IgM antibodies with IgM antibody capture
(MAC)-ELISA, even in the first (single) serum
sample; (2) by demonstration of IgM and IgG
antibodies in the second and third samples; or (3)
by demonstration of a four-fold or more signifi-
cant increase (or decrease) in the titres of specific
antibodies in paired sera. Interestingly, sera col-
lected from patients who succumb to the disease
rarely show a demonstrable antibody response.
ELISA methods (MAC-ELISA and ELISA IgG) are
quite specific and much more sensitive than
immunofluorescence and neutralisation tests
[114,115]. Serological protocols based on the
nucleocapsid protein expressed from the cloned
gene, using ELISA [116] or immunofluorescence
[117], have also been developed.
Cultivation
Blood taken during the febrile period and inocu-
lated immediately into newborn mice usually
results in infection. Viraemia generally continues
for 7–8 days, but sometimes until day 12, after the
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onset of illness. Infected blood kept at 4C
remains infective to newborn mice for 10 days,
but usually yields negative results subsequently.
Blood and plasma from patients, as well as
autopsy material (especially lung, liver, spleen,
liver, bone marrow, kidney and brain) may be
used for CCHFV isolation. Post-mortem material
should be taken within 11 h of death [118]. For
long-term storage, blood and post-mortem mater-
ial should be frozen on dry ice, in liquid nitrogen
or at ) 70C for subsequent direct isolation pro-
cedures, or at ) 20C for RT-PCR, provided that
the latter is performed shortly after storage.
CCHFV replicates poorly or not at all in most
cell lines, with no visible cytopathic effect, the
only exception being SW-13 cells derived from
human adrenal adenocarcinoma [119,120]. How-
ever, virus isolation can be achieved in cultured
Vero cells. Virus isolation can be achieved in
2–5 days, but cell cultures lack sensitivity, and
usually only allow detection of the relatively high
viraemia encountered during the first 5 days of
illness. Virus identification can be achieved sub-
sequently through immunofluorescence tests with
polyclonal antisera and ⁄ or monoclonal antibod-
ies. Intracerebral inoculation of suckling mice
necessitates specific facilities, and presents greater
risks for the laboratory worker, but is much more
sensitive, and virus can be recovered up to
13 days after the onset of illness.
Molecular methods
Classic RT-PCR methods have been described
and are becoming the method of choice for rapid
laboratory diagnosis of CCHFV infection
[105,121–123]. The quantitative assay described
by Drosten et al. [121] demonstrated that these
assays are easily capable of detecting the levels of
virus RNA typically present in acute serum
samples. Attempts to design and develop real-
time RT-PCR methods are hindered by the
extreme genetic diversity of CCHFV strains and
the lack of sequence data for the virus polymerase
gene, which would be the gene of choice, since it
probably exhibits greater homogeneity than other
virus genes.
Treatment, prevention and control
Standard treatment consists of intensive monitor-
ing and supportive care. There is no evidence that
immune plasma from recovered patients has any
beneficial effect. Ribavirin inhibits the growth of
CCHFV in vitro and in mice infected experiment-
ally [124,125]. There is anecdotal evidence that it
is effective in patients following oral and intra-
venous administration, but no formal trials of its
efficacy have been conducted [105,126]. An inac-
tivated mouse brain vaccine has been produced
and used on a small scale in the former Soviet
Union and Bulgaria, but continuation of such
production and development of a safe modern




The following viruses have also caused disease in
man, but few cases have been reported in the
literature.
Eyach virus (EYAV)
EYAV was isolated from I. ricinus in southwestern
Germany in 1976 [127]. Neutralisation and com-
plement fixation test results indicated that EYAV
and Colorado tick fever virus (CTFV; the type
species in the genus Coltivirus within the family
Reoviridae) are related antigenically to each other,
but are distinct [127]. In 1981, other strains of
EYAV were isolated in France from Ixodes ventalloi
and I. ricinus ticks [128]. EYAV was also incrim-
inated indirectly in cases of encephalitis and
polyradiduloneuritis in the former Czechoslova-
kia, since antibodies to the virus were identified
in the sera of patients with neurological syn-
drome, but without a formal identification of the
virus [129]. EYAV particles are non-enveloped,
are 70–80 nm in diameter, and possess two
concentric capsid shells with a core that is
c. 50 nm in diameter. The EYAV genome is com-
posed of 12 segments of double-stranded RNA.
The reservoir of EYAV is thought to be the
European rabbit (Oryctolagus cunniculus), but the
natural cycle of the virus is still unclear and it is
not known whether it circulates continuously in
France and Europe [130]. The virus was
re-isolated in Baden Wu¨rttemberg (Germany) in
2003, and serological surveys detected antibodies
to EYAV in rodents, including the European
rabbit (0.9%). Serological surveys in higher mam-
mals, including ovines, deer and caprines, in the
southern half of France, identified anti-EYAV
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antibodies in 1.35% of the tested animals [131].
Following the original isolation of EYAV in
France, serum from a farmer (0.2% of the tested
population) was found to be positive [128]. The
presence of anti-EYAV antibodies in sera and CSF
from 12% of patients in the former Czechoslova-
kia is an indication of the widespread distribution
of the virus in Europe [129]. Most of these patients
were diagnosed originally as suffering from a
TBEV infection.
To date, it has not been possible to propagate
EYAV in mammalian cell lines, and virus iso-
lation can be achieved only by intracranial injec-
tion of suckling mice. Complement fixation and
neutralisation assays for EYAV have been des-
cribed, but are time-consuming and difficult to
perform. Determination of the full-length genome
sequence of EYAV has allowed PCR primers to be
designed that detect as few as ten virus particles
[132], as well as the construction of a recombinant
protein used in an ELISA for detection of anti-
EYAV antibodies.
Powassan virus (POWV)
POWV, a member of the genus Flavivirus, was
isolated originally in Ontario (Canada) in 1958
from a fatally infected boy aged 5 years. Cases
have also occurred in Russia, where the virus is
transmitted by I. persulcatus and various Haema-
physalis ticks. POWV is known to have life cycles
in both ticks and mosquitoes, and this might
account for the wider geographical distribution
of this virus compared with other tick-borne
flaviviruses [133]. Apodemus mice and Microtus
voles are the principal vertebrate hosts. After an
incubation period that may last for several
weeks, clinical manifestations include fever,
headache, retro-orbital pain and photophobia,
which are usually accompanied by neurolog-
ical signs such as lethargy, generalised or focal
seizures, paresis, paralysis and focal neurological
signs.
POWV has been recovered from the brains of
patients following fatal cases of the disease.
Serological diagnosis can be achieved by detec-
tion of specific IgM antibody in acute serum or
spinal fluid, or by observing seroconversion.
However, because of possible cross-reactions
with other flaviviruses, neutralisation assays are
required for aetiological confirmation.
Louping ill virus (LIV)
LIV is another member of the genus Flavivirus
that mostly causes encephalitis in sheep. The
term ‘louping ill’ is ancient, and was used in the
18th century to describe a disease of sheep,
occurring in the Border counties of England and
Scotland, where sheep were farmed intensively
on the hillsides [134]. LIV variants circulate in
European countries other than the UK, such as
Spain (Spanish sheep encephalomyelitis virus),
Turkey (Turkish sheep encephalomyelitis virus)
and Greece (Greek goat encephalomyelitis
virus). These are probably derived from TBEV,
and have evolved in different ecological niches
[133]. They are antigenically and genetically
related closely to TBEV and LIV, and are all
capable of infecting man. LIV is transmitted by
I. ricinus ticks. Naturally-acquired human infec-
tions have occurred mainly in individuals with
occupational exposure, such as sheep farmers,
veterinarians, slaughterhouse workers or but-
chers who had direct contact with animals.
Thus, a seroprevalence rate of 8% has been
reported in abattoir workers, indicating that
exposed individuals often develop asympto-
matic infection. Laboratory-acquired infections
are common, suggesting that the virus might be
transmitted by direct mucous or respiratory
pathways. Tick-transmitted cases are scarce,
but have also been reported. Seventeen human
cases of natural infection and 26 of laboratory-
acquired infection had been described by 1991
[135].
The clinical picture is very similar to that
of the biphasic meningitis typical of western
European TBEV. After an incubation period,
generally 4–7 days, patients present with a self-
limited influenza-like illness with fever, head-
ache, dizziness, retro-orbital pain, articular pain
and myalgias [135]. This first phase is followed
by clinical improvement and, in 50% of cases,
by an encephalitic phase. Some patients devel-
op a petechial rash, with leukopenia in the first
stage and leukocytosis in the second. Infection
should be suspected in a patient presenting
with neurological manifestations and an occu-
pational context, and can be confirmed by
demonstration of specific IgM antibody or a
four-fold rise in antibody level in serum or
CSF.
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